Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal
CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule for...